• PDF: Delivered by email usually within 12 to 24 UK business hours.

Teva Pharmaceutical Industries Limited – Product Pipeline Review
2012

Teva Pharmaceutical Industries Limited – Product Pipeline Review 2012

Teva Pharmaceutical Industries Limited - Product Pipeline Review - 2012

Summary

Global Markets Direct's pharmaceuticals report, 'Teva Pharmaceutical Industries Limited - Product Pipeline Review - 2012' provides data on the Teva Pharmaceutical Industries Limited's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct's proprietary databases, Teva Pharmaceutical Industries Limited's corporate website, SEC filings, investor presentations and featured press releases, both from Teva Pharmaceutical Industries Limited and industry-specific third party sources, put together by Global Markets Direct's team.

Scope

  • Teva Pharmaceutical Industries Limited - Brief Teva Pharmaceutical Industries Limited overview including business description, key information and facts, and its locations and subsidiaries.
  • Review of current pipeline of Teva Pharmaceutical Industries Limited human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of Teva Pharmaceutical Industries Limited with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
  • Recent updates of the Teva Pharmaceutical Industries Limited's pipeline in the last quarter.
  • Key discontinued and dormant projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Evaluate Teva Pharmaceutical Industries Limited's strategic position with total access to detailed information on its product pipeline.
  • Assess the growth potential of Teva Pharmaceutical Industries Limited in its therapy areas of focus.
  • Identify new drug targets and therapeutic classes in the Teva Pharmaceutical Industries Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
  • Exploit collaboration and partnership opportunities with Teva Pharmaceutical Industries Limited.
  • Avoid Intellectual Property Rights related issues.
  • Explore the dormant and discontinued projects of Teva Pharmaceutical Industries Limited and identify potential opportunities in those areas.

This report covers the following industry codes:

  • SIC Code: 2834
  • NAICS Code: 325412
  • Teva Pharmaceutical Industries Limited Snapshot
  • Teva Pharmaceutical Industries Limited Overview
  • Key Information
  • Key Facts
  • Teva Pharmaceutical Industries Limited - Research and Development Overview
  • Key Therapeutic Areas
  • Teva Pharmaceutical Industries Limited - Pipeline Review
  • Pipeline Products by Stage of Development
  • Pipeline Products - Monotherapy
  • Pipeline Products - Combination Treatment Modalities
  • Teva Pharmaceutical Industries Limited - Pipeline Products Glance
  • Teva Pharmaceutical Industries Limited - Late Stage Pipeline
  • Teva Pharmaceutical Industries Limited Clinical Stage Pipeline Products
  • Teva Pharmaceutical Industries Limited - Early Stage Pipeline Products
  • Teva Pharmaceutical Industries Limited - Drug Profiles
  • 6-Mercaptopurine DR
  • DR-102
  • DR-104
  • DR-105
  • DR-3001
  • Laquinimod
  • Neugranin
  • Nuvigil
  • Pagoclone
  • Quartette
  • Recombinant Glycopegylated GCSCF
  • RX-3117
  • TL011
  • TL011 + Cyclophosphamide + Doxorubicin + Vincristine + Prednisone
  • TV-1011
  • TV-1011 + Docetaxel
  • TV-1011 + Mitoxantrone
  • TV-1011 + Prednisone + Docetaxel
  • VX15
  • XM17
  • XMT-1107
  • Teva Pharmaceutical Industries Limited - Pipeline Analysis
  • Teva Pharmaceutical Industries Limited - Pipeline Products by Therapeutic Class
  • Teva Pharmaceutical Industries Limited - Pipeline Products By Target
  • Teva Pharmaceutical Industries Limited - Pipeline Products by Route of Administration
  • Teva Pharmaceutical Industries Limited - Pipeline Products By Mechanism of Action
  • Teva Pharmaceutical Industries Limited - Recent Pipeline Updates
  • Teva Pharmaceutical Industries Limited - Dormant Projects
  • Teva Pharmaceutical Industries Limited - Discontinued Pipeline Products
  • Discontinued Pipeline Product Profiles
  • Teva Pharmaceutical Industries Limited - Company Statement
  • Teva Pharmaceutical Industries Limited - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
  • Teva Pharmaceutical Industries Limited, Recent Developments
  • Teva Pharmaceutical Industries Limited- Press Release
  • Financial Deals Landscape
  • Teva Pharmaceutical Industries Limited, Deals Summary
  • Teva Pharmaceutical Industries Limited, Pharmaceuticals & Healthcare, Deal Details
  • Asset Transactions
  • Venture Financing
  • Partnerships
  • Licensing Agreements
  • Equity Offering
  • Debt Offering
  • Asset Transactions
  • Acquisition
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
  • List of Tables
    • Teva Pharmaceutical Industries Limited, Key Information
    • Teva Pharmaceutical Industries Limited, Key Facts
    • Teva Pharmaceutical Industries Limited - Pipeline by Indication, 2012
    • Teva Pharmaceutical Industries Limited - Pipeline by Stage of Development, 2012
    • Teva Pharmaceutical Industries Limited - Monotherapy Products in Pipeline, 2012
    • Teva Pharmaceutical Industries Limited - Combination Treatment Modalities in Pipeline, 2012
    • Teva Pharmaceutical Industries Limited - Filed, 2012
    • Teva Pharmaceutical Industries Limited - Phase III, 2012
    • Teva Pharmaceutical Industries Limited - Phase II, 2012
    • Teva Pharmaceutical Industries Limited - Phase I, 2012
    • Teva Pharmaceutical Industries Limited - Pre-Clinical, 2012
    • Teva Pharmaceutical Industries Limited - Pipeline By Therapeutic Class, 2012
    • Teva Pharmaceutical Industries Limited - Pipeline By Target, 2012
    • Teva Pharmaceutical Industries Limited - Pipeline By Route of Administration, 2012
    • Teva Pharmaceutical Industries Limited - Pipeline Products By Mechanism of Action, 2012
    • Teva Pharmaceutical Industries Limited - Recent Pipeline Updates, 2012
    • Teva Pharmaceutical Industries Limited - Dormant Developmental Projects,2012
    • Teva Pharmaceutical Industries Limited - Discontinued Pipeline Products, 2012
    • Teva Pharmaceutical Industries Limited, Other Locations
    • Teva Pharmaceutical Industries Limited, Subsidiaries
    • Teva Pharmaceutical Industries Limited, Deals Summary
    • Cephalon To Acquire Assets Related To Larazotide Acetate From Alba Therapeutics
    • Cephalon Acquires VOGALENE And VOGALIB From UCB Pharma
    • Anesta Acquires Amrix From ECR Pharma
    • Yissum Research Sells Asthama Treatment Rights To Teva Pharma
    • Gamida Cell Raises $10 Million In Series E Financing
    • Teva Pharma Industries Invests In MultiGene Vascular Systems
    • SymBio Pharma Secures $24.5 Million In Series E Financing Round
    • VBL Biogenics Secures $40 Million In Venture Financing
    • SymBio Pharma Secures $8 Million In Second Tranche Of Series D Financing
    • MultiGene Vascular Systems Secures $8.5 Million In Venture Financing
    • Cell Cure Neurosciences Raises $0.81 Million In Venture Financing
    • SymBio Pharma Receives Investment In Second Tranche Of Series C Financing
    • Dynamix Pharma Secures $10 Million In Series A Financing
    • Vaccinex Secures $25 Million In Series B Venture Financing Round
    • Cell Cure Secures $1 Million In Venture Financing
    • Gamida Cell Secures $16 Million In Financing
    • Transpharma Medical Secures $18 Million In Series C Financing
    • Teva Pharma Industries Amends Licensing Agreement With Active Biotech
    • Antares Pharma Signs Licensing Agreement With Teva Pharma Industries
    • Teva Pharma Forms Joint Venture With Procter & Gamble
    • Teva Pharma Enters Into Co-Development Agreement With Cocrystal Discovery
    • ERYtech Pharma Enters Into Distribution Agreement With Teva For Graspa
    • Champions Biotech Enters Into An Agreement With Cephalon
    • Teva Pharma Industries Enters Into Co-Development Agreement With Alcobra
    • Celator Pharma Extends Research Agreement With Cephalon
    • Auspex Pharma Enters Into Co-Development Agreement With Teva Pharma Industries
    • Teva Pharma Enters Into Co-Development Agreement With MediWound And Polyheal
    • Celator Pharma Expands Research Agreement With Cephalon
    • Cancer Research Technology Enters Into Co-Development Agreement With Cephalon
    • H. Lundbeck Expands Marketing Agreement With Teva Pharma Industries
    • Celator Pharma Enters Into Research Agreement With Cephalon
    • Teva Pharma Industries Forms Joint Venture With Lonza Group
    • Dynamix Pharma Enters Into Co-Development Agreement With Teva Pharma
    • Teva Pharma Enters Into An Agreement With Rosetta Genomics
    • Teva Pharma Enters Into Co-Development Agreement With Jexys Pharma
    • Euroscreen Expands Co-Development Agreement With Cephalon
    • Teva Pharma Industries Signs Joint Venture Agreement With Kowa Company
    • Capricorn Pharma Enters Into An Agreement With Teva Pharma
    • Teva Pharma Industries Signs An Agreement With UCB
    • Andromeda Biotech Enters Into Collaboration With Teva Pharma
    • PsychoGenics Enters Into Drug Discovery Agreement With Cephalon
    • Compugen Enters Into Co-Development Agreement With Teva Pharma
    • Anchen Pharma Enters Into Distribution Agreement With Teva Pharma
    • Vaccinex Enters Into Co-Development Agreement With Teva Pharma Industries
    • Orphan Europe Enters Into Distribution Agreement With Teva Pharma
    • Teva Enters Into Distribution Agreement With Se-cure Pharma For Femarelle
    • Ambit Biosciences Enters Into An Agreement With Cephalon
    • Teva Pharma Enters Into An Agreement With Protalix Biotherapeutics
    • Teva Pharma Enters Into An Agreement With Procognia
    • Perrigo Enters Into Agreement With Cephalon
    • Cephalon Enters Into Agreement With Takeda
    • CureTech Enters Into Co-Development Agreement With Teva Pharma
    • Pharmacopeia Enters Into A Co-Development Agreement With Cephalon
    • Teva Pharma Enters Into Agreement With Neurosurvival Technologies
    • Mylan Technologies Enters Into Strategic Agreement With Cephalon
    • Watson Pharma Enters Into Licensing Agreement With Teva Pharma
    • Sanofi-Aventis Enters Into Licensing Agreement With Barr And Teva
    • Teva Pharma Enters Into Licensing Agreement With Proteologics
    • King Pharma Enters Into Licensing Agreement With Teva Pharma
    • DeveloGen Enters Into Licensing Agreement With Teva Pharma
    • Teva Pharma Enters Into Licensing Agreement With Biovail
    • BioAlliance Pharma Enters Into Licensing Agreement With Teva Pharma For Sitavig
    • Sinclair IS Pharma Enters Into Licensing Agreement With Teva Pharma For episil
    • CEL-SCI Expands Licensing Agreement With Teva Pharma For Multikine
    • Lundbeck Enters Into Licensing Agreement With Cephalon
    • APP Pharma Enters Into Licensing Agreement With Teva Pharma For Gemcitabine HCI
    • ImmunGene Enters Into Licensing Agreement With Cephalon
    • Cephalon Enters Into Licensing Agreement With Mesoblast For Regenerative Medicine
    • Cell Cure Neurosciences And Hadasit Bio-Holdings Enter Into Licensing Option Agreement With Teva Pharma Industries For OpRegen
    • SymBio Pharma Enters Into Licensing Agreement With Cephalon
    • AstraZeneca Enters Into Licensing Agreement With Teva Pharma For Entocort EC
    • Mersana Therapeutics Enters Into Licensing Agreement With Teva Pharma Industries
    • Sanofi, Debiopharm Enters Into Licensing Agreement With Sandoz, Fresenius & Teva
    • Innate Immune Enters Into Licensing Agreement With Cephalon Australia
    • MediGene Enters Into Licensing Agreement With Teva Pharma
    • Teva Pharma Enters Into Licensing Agreement With Oncogenex Pharma For OGX-011
    • Codexis Extends Collaboration Agreement With Teva Pharma Industries
    • Rexahn Pharma Enters Into Licensing Agreement With Teva Pharma
    • Acusphere Amends Licensing Agreement With Cephalon
    • Teva Pharma Enters Into Licensing Agreement With Andromeda Biotech
    • Cephalon Enters Into Licensing Agreement With SymBio Pharma
    • Cephalon Enters Into Licensing Agreement With ImmuPharma For Lupuzor
    • Codexis Enters Into Licensing Agreement With Teva Pharma
    • Acusphere Enters Into Licensing Agreement With Cephalon For AI-525
    • Indevus Pharma Enters Into Licensing Agreement With Teva Pharma
    • CEL-SCI Enters Into Licensing Agreement With Teva Pharma
    • Acusphere Enters Into Licensing Agreement With Cephalon
    • Antisense Therapeutics Enters Into Licensing Agreement With Teva Pharma
    • Antares Pharma Enters Into Licensing Agreement With Teva Pharma
    • GlaxoSmithKline Enters Into Licensing Agreement With Teva Pharma
    • Teva Pharma Enters Into Licensing Agreement With MediWound
    • Compugen Enters Into Licensing Agreement With Teva Pharma
    • Synerx Pharma Enters Into Licensing Agreement With Teva Pharma
    • Ambrilia Biopharma Enters Into Licensing Agreement With Teva Pharma
    • Cephalon Completes Public Offering Of $300 Million
    • Teva Pharma Completes Public Offering Of Senior Notes Due 2018 For $495 Million
    • Teva Pharma Completes Public Offering Of Senior Notes Due 2019 For $1.3 Billion
    • Teva Pharma Completes Public Offering Of Floating Rate Senior Notes Due 2013 For $200 Million
    • Teva Pharma Completes Public Offering Of Floating Rate Senior Notes Due 2013 For $1.1 Billion
    • Teva Pharma Completes Public Offering Of 1.7% Senior Notes Due 2014 For $1 Billion
    • Teva Pharma Completes Public Offering Of 2.4% Senior Notes Due 2016 For $950 Million
    • Teva Pharma Completes Public Offering Of 3.65% Senior Notes Due 2021 For $875 Million
    • Teva Pharma Completes Public Offering Of 3.65% Senior Notes Due 2021 For $875 Million
    • Teva Pharma Completes Public Offering Of Senior Notes Due 2014 For $500 Million
    • Teva Pharma Completes Public Offering Of Senior Notes Due 2014 For $250 Million
    • ChemGenex Completes Private Placement Of Convertible Notes For $15 Million
    • Teva Pharma Completes Private Placement Of 1.5% Senior Notes For $1,000 Million
    • Teva Pharma Completes Private Placement Of Senior Notes For $500 Million
    • Teva Pharma Completes Private Placement Of 3% Fixed Rate Senior Notes For $1,000 Million
    • Cephalon Completes Public Offering Of Convertible Senior Subordinated Notes For $500 Million
    • Teva Completes Public Offering Of 0.25% Debentures For $575 Million
    • Teva Completes Public Offering Of 1.75% Debentures For $818 Million
    • Teva Completes Public Offering Of 5.55% Senior Notes For $500 Million
    • Teva Completes Public Offering Of 6.15% Senior Notes For $1,000 Million
    • Halo Pharma To Acquire Mirabel Manufacturing Facility Of Teva Canada
    • Par Pharma Acquires Rights And Assets To Three Products From Teva Pharma
    • Cephalon To Divest Mitry-Mory Manufacturing Facility
    • Perrigo Acquires Rights For Allegra From Teva Pharma
    • OPKO Acquires Worldwide Ophthalmic Rights To Budesonide From Teva
    • Aero Pharma Acquires Baker Cummins Dermatology Products And US Rights From IVAX Labs
    • Teva Completes Acquisition Of Cephalon For $6,800 Million
    • Teva Pharma To Acquire Remaining 50% Joint Venture Stake In Teva-Kowa Pharma For $150 Million
    • Teva Pharma Invests Additional $19 Million In CureTech
    • Teva Pharma Industries Acquires Taiyo Pharma Industry
    • Cephalon Acquires 91.73% Stake In ChemGenex
    • Cephalon Acquires Gemin X Pharma
    • Clal Biotech Acquires Stake In TransPharma Medical From Teva
    • Cephalon Completes Acquisition Of 20% Stake In Mesoblast
    • Teva Pharma Industries Acquires Corporacion Infarmasa
    • Teva Pharma Industries Acquires THERAMEX From Merck Serono
    • Cephalon Acquires BioAssets Development
    • Teva Pharma Industries Completes Acquisition Of ratiopharm
    • Cephalon Acquires Mepha Pharma
    • Cephalon Acquires Ception Therapeutics
    • Cephalon Acquires Arana Therapeutics
    • Teva Pharma Acquires Barr Pharma
    • Paul Kennedy And Patrice Debregeas Acquire 72% Stakes In IVAX Diagnostics From Teva Pharma Industries
    • Teva Pharma Acquires Bentley Pharma
    • Teva Pharma Acquires CoGenesys From New Enterprise, Orbimed and Red Abbey
    • Teva Acquisition Of Med Ilac
    • Kedrion Acquires Human Bioplazma
    • Teva Pharma Industries Acquires An Additional 15% Stake In Tianjin Hualida Biotech
    • Teva Pharma Acquires Ivax
  • List of Figures
    • Teva Pharmaceutical Industries Limited - Pipeline by Indication, 2012
    • Teva Pharmaceutical Industries Limited - Pipeline by Stage of Development, 2012
    • Teva Pharmaceutical Industries Limited - Monotherapy Products in Pipeline, 2012
    • Teva Pharmaceutical Industries Limited - Combination Treatment Modalities in Pipeline, 2012
    • Teva Pharmaceutical Industries Limited - Pipeline By Therapeutic Class, 2012
    • Teva Pharmaceutical Industries Limited - Pipeline By Route of Administration, 2012
    • Teva Pharmaceutical Industries Limited - Pipeline Products By Mechanism of Action, 2012
+44 20 8816 8548

Ask a question about Teva Pharmaceutical Industries Limited – Product Pipeline Review

Enter the characters you see in the picture below
Captcha